Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00136539 | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | PHASE2 | COMPLETED | 41 | — | — | Mar 1, 1999 | Mar 1, 2012 | Feb 18, 2013 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Herceptin | DRUG | Given intravenously once weekly for 12 weeks prior to surgery. |
| Taxol | DRUG | Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery. |
| Adriamycin | DRUG | Given every three weeks for 12 weeks after surgery. |
| Cytoxan | DRUG | Given every three weeks for 12 weeks after surgery. |
Inclusion Criteria: * Patients must have Stage II or III histologically diagnosed breast cancer * Primary invasive breast cancers that overexpress the HER2/neu oncogene * Age older than 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of \< 1 * White blood cell (WBC) \> 4000/...